NRx Pharmaceuticals (NASDAQ:NRXP) Updates FY 2023 Earnings Guidance

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) updated its FY 2023 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -0.400–0.400 for the period, compared to the consensus estimate of -0.370. The company issued revenue guidance of -.

NRx Pharmaceuticals Stock Down 11.0 %

NRXP opened at $0.47 on Friday. The company’s 50-day moving average price is $0.47 and its 200 day moving average price is $0.38. NRx Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.20. The firm has a market cap of $43.62 million, a price-to-earnings ratio of -0.93 and a beta of 0.99.

NRx Pharmaceuticals’s stock is set to reverse split before the market opens on Tuesday, April 2nd. The 1-10 reverse split was announced on Tuesday, April 2nd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 2nd.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of NRXP. Bank of New York Mellon Corp bought a new stake in shares of NRx Pharmaceuticals during the 1st quarter worth $25,000. Citigroup Inc. increased its holdings in shares of NRx Pharmaceuticals by 355.1% during the 1st quarter. Citigroup Inc. now owns 15,208 shares of the company’s stock worth $37,000 after purchasing an additional 11,866 shares during the period. HRT Financial LP bought a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $29,000. Bank of America Corp DE increased its stake in NRx Pharmaceuticals by 10,884.4% during the fourth quarter. Bank of America Corp DE now owns 35,809 shares of the company’s stock valued at $40,000 after acquiring an additional 35,483 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $49,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.

Further Reading

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with's FREE daily email newsletter.